Trial · NCT04174612
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
NCT04174612, Phase 3, Unknown, Gruppo Italiano Malattie EMatologiche dell'Adulto
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance. Trials, record NCT04174612. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04174612
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
- NCT number
- NCT04174612
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 172 participants, estimated
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Interventions
- Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
- First posted
- 2019-11-22
- Last updated
- 2022-03-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event Free Survival | 2,5 years | Improvement of outcome measured as event-free survival (EFS) in patients with FLT3+ acute myeloid leukemia who are predicted to have low chemosensitivity, as defined upon the biomarker "peripheral blast clearance (PBC)", following the application of an early intensification of overall treatment, both in induction (high-doses delivery) and in consolidation (allocation to allogeneic transplant) phase, compared with standard regimens |
| Secondary | Adverse events rate | 2,5 years | Adverse events rate according to CTCAE criteria |
| Secondary | Rate of death in aplasia | 2 months | rate of death in aplasia |
| Secondary | Neutrophil recovery | 2 months | Median number of days for neutrophil recovery |
| Secondary | platelet recovery | 2 months | Median number of days for platelet recovery |
| Secondary | CR rate | 6 months | Complete remission rate after induction |
| Secondary | DFS | 2 years | Disease-free survival |
| Secondary | OS | 2 years | Overall survival |
| Secondary | CIR | 2 years | Cumulative incidence of relapse |
| Secondary | MRD assessment | 6 months | MRD negativity rate at the end of induction and consolidation |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04174612
GET https://conductscience.org/api/trials/v1/NCT04174612/registered